TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21234625
Drug: Targeted school-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted school-based drama group therapy (DGT)
Study: 12594112
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment (group 1)
Study: 12594112
Drug: Simulated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulated treatment (group 2)
Study: 9028062
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with antituberculous drugs and corticosteroids
Study: 6293264
Drug: Cyclic treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment with chlorambucil, methotrexate and 5‐fluorouracil
Study: 27650094
Drug: Heyan Kuntai
Normalized name: niacinamide
DrugBank: Nicotinamide (DB02701)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heyan Kuntai Capsule (HYKT)
Study: 27345931
Drug: Inhaled levodopa
Normalized name: levodopa Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled levodopa formulation (CVT-301)
Study: 24995515
Drug: Albinterferon (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albinterferon (various doses/regimens)
Study: 23523026
Drug: Ultrasound-assisted extraction
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted extraction of phenolic compounds using 1g plant sample with 12 mL of 35% ethanol for 40 min.
Study: 23523026
Drug: Ultrasound-assisted extraction
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-assisted extraction of phenolic compounds
Study: 21078951
Drug: BMS‐488043 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐488043 800 mg
Study: 21078951
Drug: BMS‐488043 1,800
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMS‐488043 1,800 mg
Study: 19588284
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (S)
Study: 16723058
Drug: Nicorandil 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil 0.1 mg kg‐1 (Group N)
Study: 9459045
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg enteric-coated tablet taken under fasting conditions
Study: 9459045
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg enteric-coated tablet taken before breakfast
Study: 9459045
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg enteric-coated tablet taken after breakfast
Study: 7932957
Drug: Biological valves
Normalized name: AmproMed for Calves
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological valves
Study: 29650371
Drug: Turo group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Turo group (8-week Turo training program, 60-minute sessions twice a week)
Study: 29650371
Drug: Waiting-list control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting-list control group (no additional treatment during the same period)
Study: 26244978
Drug: Selective Cytopheretic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective Cytopheretic Device (SCD) therapy
Study: 26244978
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT) alone
Study: 10819810
Drug: Nonoxynol 9
Normalized name: Nonoxynol 9
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoxynol 9 suppository (150 mg, intravaginally for 3 consecutive nights)
Study: 10819810
Drug: Metronidazole (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (2 g, single oral dose)
Study: 6090368
Drug: Misonidazole (2.1-2.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misonidazole (2.1-2.7 g/m2 per treatment day, given 4 hours before irradiation)
Study: 25688059
Drug: CT plus
Normalized name: Protect Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT plus Bev (7.5 mg/kg)
Study: 19236580
Drug: Duodenal acid
Normalized name: Sus scrofa duodenum preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal acid perfusion (0.2 N, 5 mL min(‐1))
Study: 8610912
Drug: succinylcholine 1
Normalized name: Succinylcholine 124 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1 mg/kg
Study: 29508689
Drug: ANPEP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ANPEP treatment
Study: 26663152
Drug: Aleglitazar (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleglitazar (150 µg once daily)
Study: 19092244
Drug: Crofelemer 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer 500 mg
Study: 19092244
Drug: Crofelemer 125
Normalized name: crofelemer 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer 125 mg
Study: 19092244
Drug: Crofelemer 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crofelemer 250 mg
Study: 16145414
Drug: Doxazosin controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin controlled release gastrointestinal therapeutic system formulation (4 mg once daily)
Study: 16145414
Drug: Propiverine hydrochloride
Normalized name: propiverine hydrochloride
DrugBank: Propiverine (DB12278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine hydrochloride (20 mg once daily) plus doxazosin controlled release gastrointestinal therapeutic system formulation
Study: 10418762
Drug: CGP 56697
Normalized name: Leucoflex CGP KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGP 56697 (4 x 4 tablets over 48 h)
Study: 10418762
Drug: Halofantrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (3 x 2 tablets over 12 h with a second course 1 week later)
Study: 7027988
Drug: Behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavior therapy package
Study: 4074113
Drug: Insight-oriented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insight-oriented therapy
Study: 28234437
Drug: Active drugs
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drugs (mood stabilizer plus adjunctive antidepressant)
Study: 24067460
Drug: S-based compound
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-based compound (NaSH)
Study: 19478215
Drug: GFR 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR 50 to 59 mL/min/1.73 m2
Study: 19478215
Drug: GFR <50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GFR <50 mL/min/1.73 m2
Study: 12093952
Drug: Forced use
Normalized name: benzalkonium chloride Topical Solution [Clean Force]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced use treatment (plaster cast on unimpaired arm for 1 month)
Study: 28034987
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and specific neck exercises
Study: 18436150
Drug: Brief psychosocial/behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief psychosocial/behavioral intervention plus antidepressant
Study: 18436150
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care including antidepressants
Study: 15151516
Drug: Montelukast (ML)
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast (ML) 10 mg
Study: 7552181
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose inhaler
Study: 31216321
Drug: modulated electro-hyperthermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: modulated electro-hyperthermia (mEHT) administered 2/weekly immediately before external beam radiation
Study: 22169051
Drug: SC golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC golimumab 100 mg every 4 weeks through week 20 (n = 33)
Study: 22169051
Drug: IV golimumab
Normalized name: Golimumab
DrugBank: Golimumab (DB06674)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV golimumab 2 mg/kg at weeks 0 and 12 (n = 16)
Study: 18175518
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol 2 mg daily
Study: 18175518
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 0.05 mg daily
Study: 10218748
Drug: COER-verapamil (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: COER-verapamil (180 to 480 mg)
Study: 10218748
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS (30 to 120 mg/d)
Study: 15251644
Drug: Intravenous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous insulin infusion therapy
Study: 11704175
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (mean 3.8 sessions with obstetrician and one with midwife)
Study: 11704175
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (mean 2.0 sessions)
Study: 31999297
Drug: Cessation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cessation of treatment with good visual acuity (CTGVA) group
Study: 31999297
Drug: CTGVA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: CTGVA group (as-needed treatment)
Study: 23743817
Drug: Light-emitting diodes
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light-emitting diodes therapy (LEDT)
Study: 22539379
Drug: Hemocoagulase (2U
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemocoagulase (2U daily for 2 days postoperatively)
Study: 17690713
Drug: Antigen-specific therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antigen-specific therapies
Study: 12848782
Drug: Formoterol 9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 9 micro g twice daily
Study: 10568080
Drug: Greater impairment
Normalized name: greater celandine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Greater impairment in instrumental activities of daily living
Study: 9333106
Drug: Tolcapone 100
Normalized name: tolcapone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 100 mg t.i.d.
Study: 9333106
Drug: Tolcapone 200
Normalized name: tolcapone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolcapone 200 mg t.i.d.
Study: 9333106
Drug: Tolcapone 400
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone 400 mg t.i.d.
Study: 9333106
Drug: Tolcapone 800
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tolcapone 800 mg t.i.d.
Study: 8739811
Drug: Levodopa/benserazide 100/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa/benserazide 100/25 mg (given on days 2 and 7)
Study: 1831059
Drug: Zidovudine (ZDV)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zidovudine (ZDV) 300 mg five times daily
Study: 6642790
Drug: Cadralazine (CD)
Normalized name: cadralazine
DrugBank: Cadralazine (DB13452)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadralazine (CD) 15 mg 1 X daily, increased to 20 mg 1 X daily if poor response
Study: 6642790
Drug: Dihydralazine (HD)
Normalized name: dihydralazine
DrugBank: Dihydralazine (DB12945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dihydralazine (HD) 25 mg 3 X daily, increased to 50 mg 2 X daily if poor response
Study: 30430372
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (50,000 IU caplets, administered weekly)
Study: 30430372
Drug: Placebo (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (administered weekly)
Study: 26702120
Drug: NoEx (fructose
Approvals — FDA: no, EMA: no, PMDA: no
Description: NoEx (fructose treatment alone with no exercise condition)
Study: 22574737
Drug: Sodium butyrate
Normalized name: Sodium butyrate
DrugBank: Butyric Acid (DB03568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium butyrate (80 mM) enema, twice daily for 3 days
Study: 21117498
Drug: Metformin hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride immediate-release tablet formulations
Study: 21117498
Drug: Experimental conditions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental conditions for metformin hydrochloride release
Study: 2454027
Drug: Piroxicam 40
Normalized name: piroxicam 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 40 mg daily for two days, then 20 mg once daily
Study: 2454027
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg twice daily for two days, then 375 mg twice daily
Study: 28697767
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Ezetimibe administered in the morning (8:00 am) for 6 weeks and then in the evening for the next 6 weeks
Study: 28697767
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Ezetimibe administered in the evening (8:00 pm) for the first 6 weeks and then in the morning for the following 6 weeks
Study: 28697767
Drug: Rosuvastatin and
Normalized name: rosuvastatin and ramipril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin and Ezetimibe (both administration times)
Study: 19762739
Drug: Sevoflurane inhalation
Normalized name: Sevoflurane Inhalation Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sevoflurane inhalation (<1 vol% end-tidal concentration)
Study: 17595249
Drug: rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 4 mg/d
Study: 19394661
Drug: rosiglitazone 8
Normalized name: rosiglitazone 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone 8 mg/d
Study: 15185314
Drug: PEG IFN‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG IFN‐alpha monotherapy (n = 20)
Study: 15185314
Drug: Treated subjects
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treated subjects (both PEG IFN‐alpha plus ribavirin and PEG IFN‐alpha monotherapy)
Study: 9664985
Drug: UDCA 15
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 15 mg/kg per day
Study: 2571501
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not on chronic nifedipine therapy)
Study: 321103
Drug: buprenorphine hydrochloride
Normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine hydrochloride 0.2 mg
Study: 321103
Drug: buprenorphine hydrochloride
Normalized name: Buprenorphine Hydrochloride
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine hydrochloride 0.4 mg
Study: 321103
Drug: morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine sulphate 5 mg
Study: 10692620
Drug: morphine sulphate
Normalized name: Morphine sulphate
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: morphine sulphate 10 mg
Study: 22573933
Drug: Pasireotide 200-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 200-1200 μg
Study: 22573933
Drug: Pasireotide 1-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pasireotide 1-1200 μg
Study: 19485982
Drug: Standard-dose peginterferon-alpha-2b
Normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose peginterferon-alpha-2b (1.5 microg/kg/week) plus low-dose ribavirin (200 mg/day) for extended 24 weeks (group A)
Study: 19485982
Drug: Low-dose peginterferon-alpha-2b
Normalized name: peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose peginterferon-alpha-2b (0.75 microg/kg/week) plus low-dose ribavirin for extended 48 weeks (group B)
Study: 19485982
Drug: No extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: No extended treatment (group C)
Study: 11732026
Drug: Postoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative oral antibiotics (penicillin VK, 500 mg every 6 hours for 5 days)
Study: 11732026
Drug: Placebo (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (oral placebo, same schedule as group 1)
Study: 9885688
Drug: 10 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 micrograms sufentanil added to 7.5 mg bupivacaine
Study: 9885688
Drug: 15 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 micrograms fentanyl added to 7.5 mg bupivacaine
Study: 9885688
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg bupivacaine alone
Study: 8004297
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide 800 micrograms by Turbuhaler
Study: 2129838
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg at night
Study: 2129838
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg at night
Study: 21654350
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg twice daily
Study: 23731453
Drug: Topical sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sildenafil (10%) ointment
Study: 23161898
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2 d1) and pemetrexed (500 mg/m2 d1) q3 weeks
Study: 23161898
Drug: Cisplatin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (50 mg/m2 d1 + 8) and vinorelbine (25 mg/m2 d1, 8, 15, 22) q4 weeks
Study: 17409841
Drug: Bortezomib 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bortezomib 1.0 mg/m on days 1, 4, 8, and 11 plus docetaxel 75 mg/m on day 1, cycled every 21 days.
Study: 8935812
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/day (Olz10.0)
Study: 8935812
Drug: Olanzapine 1
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 1 mg/day (Olz1.0)
Study: 1743840
Drug: Functional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional treatment with a newly designed brace
Study: 7181299
Drug: Sulphate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphate (1 mg m‐3)
Study: 7181299
Drug: Sulphate (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulphate (0.1 mg m‐3)
Study: 24843528
Drug: liraglutide 0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 0.9 mg/day
Study: 21037100
Drug: Vascular endothelial
Normalized name: Vascular endothelial growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vascular endothelial expression of mucosal addressin cell adhesion molecule-1
Study: 18097503
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum 6 mg
Study: 18097503
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum 0.6 mg
Study: 18097503
Drug: G. lucidum
Approvals — FDA: no, EMA: no, PMDA: no
Description: G. lucidum 60 mg
Study: 8269452
Drug: Loratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (5 or 10 mg once daily for 14 days)
Study: 8269452
Drug: Terfenadine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (15 mg twice daily for 14 days)
Study: 8269452
Drug: Loratadine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (5 or 10 mg once daily)
Study: 8269452
Drug: Terfenadine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (15 mg twice daily)
Study: 4041344
Drug: Acute administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute administration of nisoldipine
Study: 4041344
Drug: Continued administration
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued administration of nisoldipine
Study: 30509713
Drug: Saffron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron supplementation (100 mg/d for 8 weeks)
Study: 10394177
Drug: Citalopram therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram therapy (40 mg i.v. bolus immediately after admission to the ICU)
Study: 10394177
Drug: Citalopram therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram therapy (continuous infusion over 24 hours)
Study: 10394177
Drug: Citalopram therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram therapy
Study: 8907717
Drug: Diltiazem administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem administered at 08:00 (AM)
Study: 8907717
Drug: Diltiazem administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem administered at 22:00 (HS)
Study: 1794358
Drug: Purified pneumococcal
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified pneumococcal polysaccharide vaccines
Study: 1794358
Drug: Development of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Development of more highly immunogenic vaccines (linked polysaccharides to protein carriers)
Study: 29128300
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition (20-25 kcal/kg per day)
Study: 25925751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PHM and NMF (COMB)
Study: 21369791
Drug: Alendronate (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (5, 10, or 20 mg daily; 35 mg once-weekly; 35 mg twice-weekly; 70 mg once-weekly)
Study: 20691641
Drug: Leuprorelin 11.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin 11.25 mg subcutaneously every 12 weeks
Study: 19419930
Drug: Multitargeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitargeted therapy
Study: 19419930
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with traditional chemotherapy and radiation therapy
Study: 19419930
Drug: Multitargeted inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multitargeted inhibitors
Study: 16491252
Drug: Happydent chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Happydent chewing gum (3.38 mg of fluoride as monofluorophosphate)